A Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Phase III Study of Oral GW572016 in Combination With Paclitaxel in Subjects Previously Untreated or Advanced or Metastatic Breast Cancer
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Phase III Study of Oral GW572016 in Combination With Paclitaxel in Subjects Previously Untreated or Advanced or Metastatic Breast Cancer
The purpose of this study is to determine the efficacy and safety of an oral dual tyrosine kinase inhibitor (GW572016) in combination with paclitaxel compared to paclitaxel alone in first line advanced or metastatic breast cancer.
Inclusion criteria:
Exclusion criteria:
Buenos Aires, Buenos Aires 1425, Argentina
Capital Federal, Buenos Aires C1405CBA, Argentina
Capital Federal, Buenos Aires C1426ANZ, Argentina
Zalaegerszeg-Pózva, 8900, Hungary
Moscow Region, 143 423, Russia
Alcorcón/Madrid, 28922, Spain
Baracaldo/Vizcaya, 48903, Spain
Cuidad Real, 13002, Spain
Móstoles/Madrid, 28935, Spain